

Af

IFW

1653

Docket No. JBP0438US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Miri Seiberg et al.

Confirmation No.: 5255

Serial No.

09/206,249

Art Unit: 1655

Filed

December 7, 1998

Examiner: Michael V. Meller

For

Methods for Regulating Phagocytosis and ICAM-1 Expression

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 14, 2006
(Date of Deposit)

Andrea L. Colby, Reg. No. 30,194
(Name of applicant, assignee, or Registered Representative)

/Andrea L. Colby/
(Signature)

November 14, 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(Date of Signature)

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\boxtimes	In accordance with §1.97(b), since this Information Disclosure Statement		
is being filed e	either within three months of the filing date of the above-identified		
national applic	cation (other than a continued prosecution application under §1.53(d)),		
within three m	onths of the date of entry into the national stage of the above identified		
application as set forth in §1.491, or before the mailing date of a first Office Action on			
the merits of the above-identified application, or before the mailing date of a first Office			
Action after th	e filing of a request for continued examination under §1.114, no		
additional fee	is required.		
	In accordance with §1.97(c), this Information Disclosure Statement is		
being filed afte	er the period set forth in §1.97(b) above but before the mailing date of		
either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action			
that otherwise closes prosecution and that it is accompanied by one of:			
	Statement in Accordance with §1.97(e) (attached); or		
ļ	Please charge Deposit Account No. 10-0750 the fee of \$180.00		
	as set forth in §1.17(p).		
	In accordance with §1.97(d), this Information Disclosure Statement is		
being filed after the mailing date of either a Final Action under §1.113 or a Notice of			
Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s)			
hereby petition(s) for consideration of this Information Disclosure Statement. Included			
are: Statement in Accordance with §1.97(e) as set forth below and the fee of <u>\$180.00</u>			
as set forth in §1.17(p).			
	Copies of only foreign patent documents and non-patent literature are		
enclosed in accordance with 37 CFR 1.98 (a)(2).			
. 🗆 -	There are no listed references which are not in the English language.		
\boxtimes	The relevance of those listed references which are not in the English		
anduada is as	e follows:		

English language abstracts are on the form SB/08/A.	e provided for the foreign patent documents listed
·	search report(s) from corresponding patent attached Submission Under MPEP 609 D.
	ing non-published pending patent applications hare listed on the attached Submission Under
Please charge any deficiency of No. 10-0750/JBP438/ALC. This form	or credit any overpayment to Deposit Account is submitted in triplicate. Respectfully submitted,
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2792 DATED: November 14, 2006	/Andrea L. Colby/ Andrea L. Colby Reg. No. 30,194 Attorney for Applicants

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

d to respond to a collection of information diffess it displays a valid Owl Control fluitiber.				
Confirmation Number	5255			
Application Number	09/206,249			
Filing Date	12/07/1998			
First Named Inventor	Miri Seiberg			
Group Art Unit	1655			
Examiner Name	Michael V. Meller			
Attorney Docket Number	JBP0438US			

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Cite Kind Code where relevant passages or of Cited Document of Cited Document Initials relevant figures appear Number (if known) No.1 mm-dd-yyyy

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Publication of Lines, where relevant Name of Patentee or Cited Document passages or relevant Exam Applicant of Cited Document figures appear KindCode5 Office³ Number⁴ mm-dd-yyyy No.1 CN 1146876 Α Li 04-09-1997 English Abst. New Standard GmbH DE 4432947 Α 03-21-1996 English Abst. Α English Abst. DE Reinke Ludwig Dr. 03-05-1998 19634206 EP 0 581 624 Α1 Expanchimie SARL 02-02-1994 English Abst. EP 0 581 624 B1 Expanchimie SARL 02-02-1994 **English Claims** EP 0 582 239 **A1** Rhone-Poulenc Rorer 02-09-1994 English Abst. EP B1 Rhone-Poulenc Rorer 02-09-1994 **English Claims** 0 582 239 JP 60061513 Α Sansei Seiyaku KK 04-09-1985 English Abst. WO **A1** 01-07-1999 English Abst. 99/00110 Andre et al. 08-12-1999 WO **A2** Fernandez-Kleinlein et al. 99/39682 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

T²

T²

Examiner	Date	
Signature	Considere	red

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.